Clinical Trial Update: Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alemtuzumab, fludarabine phosphate, and low-dose total body irradiation as a conditioning regimen before donor stem cell transplantatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Hematologic Malignancies

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Donor Stem Cell Transplantation
• Fludarabine phosphate (Fludarabine phosphate)
• Low-dose total body irradiation (total body irradiation)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Status: COMPLETED | Results posted: 2017-03-16